₹1,000 Monthly SIP in Nippon India Pharma Fund-Growth Plan for 15 Years
If you had started a ₹1,000/month SIP on 29 Sept 2011 and never stopped — through every crash and rally — here is exactly what happened, using Nippon India Pharma Fund-Growth Plan's actual NAV for all 181 installments.
You invested
₹1,81,000
181 installments
Value today
₹7,13,872
29 Sept 2026
Absolute gain
+₹5,32,872
+294.4%
XIRR (annualised)
16.54%
money-weighted
The journey, month by month
Worst fall on the way
-20.7%
Deepest drop from peak. This is what you had to sit through.
Corrections survived
7
Falls of 10%+ during the period. Every one recovered.
Same SIP in a fixed deposit
₹3,36,929
Modelled at historical FD rates. The fund beat FD by ₹3,76,943.
Year-by-year progress
| Year | Invested | Value | Overall gain |
|---|---|---|---|
| Year 1 (1 Oct 2012) | ₹14,000 | ₹16,144 | +15.3% |
| Year 2 (30 Sept 2013) | ₹25,000 | ₹29,743 | +19% |
| Year 3 (29 Sept 2014) | ₹37,000 | ₹65,910 | +78.1% |
| Year 4 (29 Sept 2015) | ₹49,000 | ₹96,700 | +97.3% |
| Year 5 (29 Sept 2016) | ₹61,000 | ₹1,03,820 | +70.2% |
| Year 6 (29 Sept 2017) | ₹73,000 | ₹1,04,392 | +43% |
| Year 7 (1 Oct 2018) | ₹86,000 | ₹1,43,050 | +66.3% |
| Year 8 (30 Sept 2019) | ₹97,000 | ₹1,37,010 | +41.2% |
| Year 9 (29 Sept 2020) | ₹1,09,000 | ₹2,35,531 | +116.1% |
| Year 10 (29 Sept 2021) | ₹1,21,000 | ₹3,35,873 | +177.6% |
| Year 11 (29 Sept 2022) | ₹1,33,000 | ₹3,18,247 | +139.3% |
| Year 12 (29 Sept 2023) | ₹1,45,000 | ₹4,15,111 | +186.3% |
| Year 13 (30 Sept 2024) | ₹1,57,000 | ₹6,30,966 | +301.9% |
| Year 14 (29 Sept 2025) | ₹1,69,000 | ₹6,12,517 | +262.4% |
| Year 15 (29 Sept 2026) | ₹1,81,000 | ₹7,13,872 | +294.4% |
Best year of the journey: Year 9 (+58.1% market move) · Toughest year: Year 8 (-11.1%)
Wealth Time Machine
Watch this exact journey as a 60-second cinematic replay
Every crash headline, every recovery — with your money in it.
Try a different amount
Try a different duration
Past performance does not guarantee future returns. This page shows the historical result of the stated SIP using Nippon India Pharma Fund-Growth Plan's published NAV (source: AMFI) between 29 Sept 2011 and 29 Sept 2026; it is educational research, not investment advice. FD comparison is modelled at historical average FD rates. Mutual fund investments are subject to market risks.